Spectral Medical Inc T.EDT

Alternate Symbol(s): EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.

TSX:EDT - Post by User

Spectral Medical Inc > Baxter Reports Fourth-Quarter and Full-Year 2023 Results

<< Previous

Bullboard Posts

Next >>

Comment by hmmmmmmmmon Feb 08, 2024 6:49pm

167 Views

Post# 35871281

RE:RE:RE:RE:Baxter Reports Fourth-Quarter and Full-Year 2023 Results

We also know endotoxin burden is very significant in burn patients, and in open heart surgery patients.

There are studies in Japan dating back to 2008 using PMX for these aplications.

A company like Baxter/ Vantive would have the ability and resources to immediately apply for add on studies- adding to their "multi organ support therapies" windfall.

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale